Bispecific antibody · Immune activation, directed at hepatocyte growth factor receptor (c-Met) (MET), trophoblast cell surface antigen 2 (TROP2) (TACSTD2) and CD3 T-cell surface antigen (CD3E) · developed by ModeX Therapeutics, An OPKO Health Company
MDX2001 is a tetra-specific antibody that binds CD3 and CD28 on T cells and the tumor-associated antigens c-Met and TROP2 on tumor cells. By cross-linking T cells to tumor cells, it is intended to trigger a cytotoxic T-lymphocyte response against c-Met and TROP2-expressing tumors. It is being studied in multiple solid tumors, including gastrointestinal, lung, breast, renal and prostate cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06239194 | Phase 1/2 | Biliary Tract Cancer | Recruiting | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Biliary Tract CancerBreast CancerCervical CancerColon CancerEndometrial CancerEsophageal CancerGastric CancerGastroEsophageal CancerHead and Neck CancerHepatocellular CancerNon-small Cell Lung CancerPancreatic CancerProstate CancerRectal Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →